243 related articles for article (PubMed ID: 24169416)
1. Anti-angiogenic therapy in pediatric brain tumors: an effective strategy?
Sie M; den Dunnen WF; Hoving EW; de Bont ES
Crit Rev Oncol Hematol; 2014 Mar; 89(3):418-32. PubMed ID: 24169416
[TBL] [Abstract][Full Text] [Related]
2. Novel anti-angiogenic therapies for malignant gliomas.
Norden AD; Drappatz J; Wen PY
Lancet Neurol; 2008 Dec; 7(12):1152-60. PubMed ID: 19007739
[TBL] [Abstract][Full Text] [Related]
3. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.
Gacche RN; Meshram RJ
Prog Biophys Mol Biol; 2013 Nov; 113(2):333-54. PubMed ID: 24139944
[TBL] [Abstract][Full Text] [Related]
4. Brain angiogenesis in developmental and pathological processes: therapeutic aspects of vascular endothelial growth factor.
Shibuya M
FEBS J; 2009 Sep; 276(17):4636-43. PubMed ID: 19664071
[TBL] [Abstract][Full Text] [Related]
5. VEGF inhibitors in brain tumors.
Brastianos PK; Batchelor TT
Clin Adv Hematol Oncol; 2009 Nov; 7(11):753-60, 768. PubMed ID: 20075834
[TBL] [Abstract][Full Text] [Related]
6. Targeting angiogenesis in head and neck cancer.
Seiwert TY; Cohen EE
Semin Oncol; 2008 Jun; 35(3):274-85. PubMed ID: 18544442
[TBL] [Abstract][Full Text] [Related]
7. Anti-angiogenic therapy against gastrointestinal tract cancers.
Iwasaki J; Nihira S
Jpn J Clin Oncol; 2009 Sep; 39(9):543-51. PubMed ID: 19531544
[TBL] [Abstract][Full Text] [Related]
8. Growing tumor vessels: more than one way to skin a cat - implications for angiogenesis targeted cancer therapies.
Leite de Oliveira R; Hamm A; Mazzone M
Mol Aspects Med; 2011 Apr; 32(2):71-87. PubMed ID: 21540050
[TBL] [Abstract][Full Text] [Related]
9. Anti-VEGF therapies for malignant glioma: treatment effects and escape mechanisms.
Miletic H; Niclou SP; Johansson M; Bjerkvig R
Expert Opin Ther Targets; 2009 Apr; 13(4):455-68. PubMed ID: 19335067
[TBL] [Abstract][Full Text] [Related]
10. Angiogenesis and anti-angiogenic molecularly targeted therapies in malignant gliomas.
Argyriou AA; Giannopoulou E; Kalofonos HP
Oncology; 2009; 77(1):1-11. PubMed ID: 19439998
[TBL] [Abstract][Full Text] [Related]
11. Vascular endothelial growth factor pharmacogenetics: a new perspective for anti-angiogenic therapy.
Pasqualetti G; Danesi R; Del Tacca M; Bocci G
Pharmacogenomics; 2007 Jan; 8(1):49-66. PubMed ID: 17187509
[TBL] [Abstract][Full Text] [Related]
12. [Anti-angiogenic strategies in glioblastoma].
Guillamo JS
Rev Neurol (Paris); 2011 Oct; 167(10):662-7. PubMed ID: 21889779
[TBL] [Abstract][Full Text] [Related]
13. [Angiogenesis and anti-angiogenic strategies for glioblastoma].
de Boüard S; Guillamo JS
Bull Cancer; 2005 Apr; 92(4):360-72. PubMed ID: 15888393
[TBL] [Abstract][Full Text] [Related]
14. Antiangiogenic therapy in the management of brain tumors: a clinical overview.
Kunnakkat S; Mathew M; Narayana A
Cancer Chemother Pharmacol; 2012 Sep; 70(3):353-63. PubMed ID: 22825032
[TBL] [Abstract][Full Text] [Related]
15. Angiogenesis in malignant glioma--a target for antitumor therapy?
Tuettenberg J; Friedel C; Vajkoczy P
Crit Rev Oncol Hematol; 2006 Sep; 59(3):181-93. PubMed ID: 16860996
[TBL] [Abstract][Full Text] [Related]
16. Novel strategies towards the use of anti-angiogenic agents in breast cancer.
Bakker JL; Meijers-Heijboer H; Verheul H
Eur J Pharmacol; 2013 Oct; 717(1-3):36-9. PubMed ID: 23545363
[TBL] [Abstract][Full Text] [Related]
17. Anti-angiogenic agents for the treatment of brain tumors.
Fisher MJ; Adamson PC
Neuroimaging Clin N Am; 2002 Nov; 12(4):477-99. PubMed ID: 12687907
[TBL] [Abstract][Full Text] [Related]
18. Tumour angiogenesis: its mechanism and therapeutic implications in malignant gliomas.
Wong ML; Prawira A; Kaye AH; Hovens CM
J Clin Neurosci; 2009 Sep; 16(9):1119-30. PubMed ID: 19556134
[TBL] [Abstract][Full Text] [Related]
19. [Anti-angiogenesis treatment for brain tumors: present and future].
Takano S; Matsumura A
No Shinkei Geka; 2006 Jul; 34(7):657-78. PubMed ID: 16841703
[No Abstract] [Full Text] [Related]
20. Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist.
Alessi P; Leali D; Camozzi M; Cantelmo A; Albini A; Presta M
Eur Cytokine Netw; 2009 Dec; 20(4):225-34. PubMed ID: 20167562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
